Sep 17, 2008
Sanofi Aventis: challenges and a new strategy.
In mast in the image of all pharmaceutical values for months ..., Sanofi Aventis was buoyed this week by the appointment of Chris Viehbacher the post of director general. In the wake of this shock, the title has jumped more than 7% in the space of a meeting. In charge of pharmaceutical operations at GlaxoSmithKline for North America, Chris Viehbacher take up his duties with effect from 1st December.
Aged 48 years and having dual nationality Canadian and German, the Anglo-Saxon will succeed Gerard Le Fur whose appointment ago just 18 months at the helm of the pharmaceutical group has not convinced Total and L’Oreal, the two main shareholders of the group. Neither the Exchange. In two years, Sanofi Aventis and unscrewed by 30%.
Four years after the merger between Sanofi-Synthelabo and Aventis, the goal is to reinvigorate the strategy of the pharmaceutical company, which has been badly affected by the refusal in June 2007, U.S. health authorities, the FDA (Food and Drug Administration), to authorize the marketing of the treatment against obesity by Sanofi Aventis, Acomplia (Rimonabant). This decision was all the more unexpected that Acemplia is a genuine star in Europe.
These setbacks could have weighed in the decision to replace Gerard Le Fur whose skills have been widely shown in the research departments of Sanofi and Rhone Poulenc ... His detractors argue against it is not a big sponsor, which has been able to play against the group ...
Sanofi Aventis is more generally deal (like the big pharmaceutical companies) to lower drug prices and the loss of patents, including growing competition from generics. Moody’s has indicated early September that the European sector of the pharmacy could lose 18% of its turnover over the next three years.
Drug flagship of the group french used against arterial complications in the case, for example ... infarction, including Plavix will face from 2012 the marketing of several generic drug competitors. The Taxotere, used to treat breast cancer and lung cancer, for its part will lose its patent from 2010 in Europe and the USA ...
Sanofi Aventis was therefore obliged to react as quickly as possible to prepare the response to these deadlines ...
At the appointment of Chris Viehbacher, the Board of Directors of Sanofi-Aventis has recommended a strategy articulated around three pillars: (1) the search for innovative products better suited to the new regulatory and economic market (2) strengthening the position of the group on growth markets and (3) the further development of other activities in the fields of medicine and health.
For the new CEO of Sanofi Aventis, will therefore find a successful attempt at redemption, so far failed, laboratory Czech Zentiva, which has the double advantage of being specializes in generic drugs and strengthen the presence french group in the country to strong growth.
In early September, the direction of Zentiva, which Sanofi Aventis already holds 24.9% of the capital, in any case rejected pleas to the offer of french, which enhances the approximately 1.6 billion euros.
Sanofi Aventis intends to put a new string to its bow, by engaging more actively in health foods, such as Danone Actimel ... The first stone of the building has already been raised with the completion of the purchase of the Australian Consumer Symbion for an amount of 560 million Australian dollars (about 340 million euros) at the beginning of the year ...
Maybe you just have that Sanofi Aventis reaches to strengthen in what remains its core business, namely the ‘major’ drugs ..
by erectusplus at 11:35 AM |
0 Comments:
Post a Comment
<< Home